The effect of fenofibrate on insulin sensitivity and plasma lipid profile in nondiabetic males with low high density lipoprotein/dyslipidaemic syndrome

Annals of the Academy of Medicine Singapore

Volumn 28, Issue 6, 1999, Pages 778-782

  Yong, Q W ^a   Thavintharan, S ^b   Cheng, A ^a   Chew, L S ^b  

^a TAN TOCK SENG HOSPITAL   (Singapore)

^b Royal Alexandra Hospital   (New Zealand)

Author keywords

Fenofibrat e; Insulin resistance; Low HDL cholesterol; Non diabetic males

Indexed keywords

FENOFIBRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPID; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; CLINICAL ARTICLE; DRUG EFFECT; DYSLIPIDEMIA; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID BLOOD LEVEL; MALE; ORAL GLUCOSE TOLERANCE TEST;

EID: 0033377677     PISSN: 03044602     EISSN: 29724066     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Reaven G. Role of insulin resistance in human disease. Diabetes 1988; 37:1595.
2. Kaplan N M. The deadly quartet: Upper body obesity, glucose intolerance, hypertriglyceridaemia, and hypertension. Arch Intern Med 1989; 149:1514-5.
3. De Fronzo R A, Ferrannini E. Insulin resistance: A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidaemia and atherosclerotic cardiovascular disease. Diabetes Care 1991; 14:173-94.
4. Stout R W. Insulin and atheroma: 20-year perspective. Diabetes Care 1990; 13:631.
5. Modan M, Or J, Karasik A, Drory Y, Fuchs Z, Lusky A, et al. Hyperinsulinaemia, sex and risk of atherosclerotic cardiovascular disease. Circulation 1991; 84:1165-75.
6. Sowers J R, Sowers P S, Edelson G W. Insulin and premature ischaemic heart disease. J Myocardial Ischemia 1993; 5(Suppl 1):45-8.
7. Moan A, Os I, Hjermann I, Kjeldsen S E. Hypertension therapy and risk of coronary heart disease: how do antihypertensives affect metabolic factors? Cardiology 1995; 86:89-93.
8. Pollare T, Lithell H, Berńe C. Insulin resistance is a characteristic feature of primary hypertension independent of obesity. Metabolism 1990; 39:167-74.
9. Reaven G M. Insulin Resistance, hyperinsulinaemia and hypertriglyceridemia in the etiology and clinical course of hypertension. Am J Med 1991; 90(Suppl 2A):7-12.
10. Swislocki A L M, Huffman B B, Reaven G M. Insulin resistance, glucose intolerance and hyperinsulinaemia in patients with hypertension. Am J Hypertens 1989; 2:419-20.
11. Weber M A. Cardiovascular and metabolic characteristics of hypertension. Am J Med 1991; 91(Suppl 1A):4.
12. Tan C E, Chew L S, Sum C F, Fok A C, Wang K W. Metabolic abnormalities in young non-obese males with hypertension. Ann Acad Med Singapore 1994; 23:1:2-5.
13. Expert Panel on the Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 1993; 269:3015-23.
14. Imx® Insulin Reagent (Abbot Imx® Insulin Assay) Pack Manual. USA: Abbot Laboratories, 1993. List No. 2A10:10.
15. Lopes-Virella M F, Stone P, Shelton E, Cohwell J A. Cholesterol determination in high density lipoproteins separated by three different methods. Clin Chem 1977; 22:882-4.
16. Menard L, Dempsey ME, Blankstein LA, Aleyassine H, Wacks M, Soeldner J S. Quantitative determination of glycosylated hemoglobin Al by agar gel electrophoresis. Clin Chem 1980; 26:1598-1602.
17. Ferannini E, Haffuer S M, Stern M P. Essential hypertension. An insulin resistant state. J Cardiovasc Pharmacol 1990; 15(Suppl 5):18-25.
18. Bairaktari E T, Tzallas C S, Tsimihodimos V K, Liberopoulos E N, Miltiadous G A, Elisaf M S. Comparison of the efficacy of atorvastatin and micronized fenofibrate in the treatment of mixed hyperlipidemia. J Cardiovasc Risk 1999; 6:113-6.
19. Gholami K, Tavakoli N, Maleki M, Shafiee A J. Comparison of the efficacy and safety of fenofibrate and lovastatin in patients with primary type IIa or IIb hyperlipidaemia. Clin Pharm Ther 1998; 23:213-21.
20. Davignon J. Advances in drug treatment of dyslipidemia: focus on atorvastatin. Can J Cardiol 1998; 14:28B-38B.
21. Adkins J C, Faulds D. Micronised fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia. Drugs 1997; 54:615-33.
22. Le Floch J P, Escuyer P, Baudin E, Baudon D, Perlemuter L. Blood glucose area under the curve. Diabetes Care 1990; 13:172-5.
23. Axelsen M, Eliasson B, Joheim E, Lenner R A, Taskinen M R, Smith U. Lipid intolerance in smokers. J Intern Med 1995; 237:449-55.
24. Tenkanen L, Pietila K, Manninen V, Manttari M. The triglyceride issue revisited. Findings from the Helsinki Heart Study. Arch Intern Med 1994; 154:2714-20.
25. Austin M A, Breslow J L, Hennekens C H, Buring J E, Willett W C, Krauss R M. Low density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 1988; 260:1917-21.
26. Griffin B A, Freeman D J, Tait G W, Thomson J, Caslake M J, Packard C J, et al. Role of plasma triglyceride in the regulation of plasma LDL subfractions: relative contribution of small dense LDL to coronary heart disease. Atherosclerosis 1994; 106:241-53.
27. Lavie C J, Milani R V. National Cholesterol Education Program's recommendations and implications of "missing" HDL cholesterol in cardiac rehabilitation programs. Am J Cardiol 1991; 68:1087-8.
28. Zeiher A M, Schachlinger V, Hohnloser S H, Saurbier B, Just H. Coronary atherosclerotic wall thickening and vascular reactivity in humans: elevated HDL cholesterol ameliorate abnormal vasoconstriction in early atherosclerosis. Circulation 1994; 89:2525-32.
29. Kitamura A, Iso H, Naito Y, Iida M, Konishi M, Folsom AR, et al. High density lipoprotein cholesterol and premature coronary artery disease in urban Japanese men. Circulation 1994; 89:2533-9.
30. Corti M C, Guralnik J M, Salive M E, Harris T, Field T S, Wallace R B, et al. HDL cholesterol predicts coronary heart disease mortality in older persons. JAMA 1995; 274:539-44.
31. Milani R V, Lavie C J. Assessment and management of patients with low levels of HDL cholesterol. J Myocardial Ischemia 1992; 4:27-45.
32. Rubins H B, Robins S J, Collins D, Iranmanesh A, Wilt T J, Mann D, et al. Distribution of lipids in 8,500 men with coronary artery disease. Department of Veterans Affairs HDL Intervention Trial Study Group. Am J Cardiol 1995; 75:1196-201.
33. Kashyap M L. Cholesterol and atherosclerosis: a contemporary perspective [review]. Ann Acad Med Singapore 1997; 26:517-23.